All In Biotech

Drug Trial Radar · NCT07659574

Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone(UNIGUIDE-1)

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Trial to Evaluate the Efficacy and Safety of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone(UNIGUIDE-1)

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Sep 7, 2026

Primary completion

Sep 24, 2027

Study completion Oct 22, 2027

Sponsor

Sponsor type
Industry
First posted
Jun 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, randomized, double-Blind, parallel-group, placebo-controlled phase III trial is to evaluate the efficacy and safety of UBT251 Injection in patients with Type 2 Diabetes Mellitus with inadequate glycemic control on diet and exercise alone

Conditions

  • Type 2 Diabetes

Interventions

  • UBT251 Injection 2.0 mgDrug

    UBT251 Injection subcutaneously once weekly

  • UBT251 Injection 4.0 mgDrug

    UBT251 Injection subcutaneously once weekly

  • UBT251 Injection 6.0 mgDrug

    UBT251 Injection subcutaneously once weekly

  • UBT251 Injection Placebo 2.0 mgDrug

    UBT251 Injection placebo subcutaneously once weekly

  • UBT251 Injection Placebo 4.0 mgDrug

    UBT251 Injection placebo subcutaneously once weekly

  • UBT251 Injection Placebo 6.0 mgDrug

    UBT251 Injection placebo subcutaneously once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1cTime frame: Week 40

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.